YAP、p65与弥漫大B细胞淋巴瘤临床特征的相关性及临床意义

doi:10.20223/j.cnki.1000-8535.2024.12.002

广州医药 ›› 2024, Vol. 55 ›› Issue (12): 1389-1396.DOI: 10.20223/j.cnki.1000-8535.2024.12.002

YAP、p65与弥漫大B细胞淋巴瘤临床特征的相关性及临床意义

何人可, 林子怡, 张闻开, 陈远林, 张东辉, 邓晓芳

广州医科大学附属肿瘤医院内二科（广东广州 510095）

收稿日期:2024-09-02 出版日期:2024-12-20 发布日期:2025-01-08
通讯作者: 邓晓芳,E-mail：dengxf2046@126.com
基金资助:
国家自然科学基金（81800153）

Correlation and clinical significance of YAP and p65 with clinical features of diffuse large B-cell lymphoma

HE Renke, LIN Ziyi, ZHANG Wenkai, CHEN Yuanlin, ZHANG Donghui, DENG Xiaofang

Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Second Department of Medical Oncology, Guangzhou 510095, China

Received:2024-09-02 Online:2024-12-20 Published:2025-01-08

摘要/Abstract

摘要： 目的探讨Yes1相关蛋白（YAP）及p65在弥漫大B细胞淋巴瘤（DLBCL）中与临床特征的相关性及对DLBCL治疗和预后的意义。方法收集65例DLBCL和10例反应性增生淋巴结患者组织进行免疫组织化学染色,分析两组差异;对多种临床特征与YAP、p65的相关性进行统计学和生存差异性分析。结果 YAP、p65染色评分在两组间比较差异有统计学意义（P<0.05）;YAP评分与疗效分组呈正相关,与治疗前乳酸脱氢酶（LDH）、Ann-Arbor分期、国际预后指数（IPI）呈负相关（P<0.05）;p65表达与疗效分组呈负相关,与治疗前LDH水平、Ann-Arbor分组、美国东部肿瘤协作组活动状态评分（ECOG）ECOG分组、结外侵犯、IPI评分、巨大包块呈正相关（P<0.05）。IPI及p65评分是DLBCL患者总生存期（OS）的独立危险因素（P<0.05）。共表达分层中YAP-/p65⁺组患者OS均值最低。结论对于DLBCL,YAP低表达或p65高表达提示患者瘤荷较大、较差的疗效和预后。

关键词: DLBCL, Hippo通路, YAP, NF-κB通路, p65

Abstract: Objective To investigate the correlation of YAP and p65 with clinical features in diffuse large B-cell lymphoma（DLBCL）and the significance for treatment and prognosis．Methods Tissues from 65 patients with DLBCL and 10 patients with reactive hyperplasia lymph node were collected for immunohistochemistry staining to analyze the differences between the two groups;statistical analysis and survival difference analysis of the correlation between various clinical features and YAP,p65 were performed．Results YAP and p65 staining scores were significantly different between the two groups（P<0.05）．YAP scores were positively correlated with efficacy subgroups,and negatively correlated with LDH levels before treatment,Ann-Arbor staging,and International Prognostic Index（IPI）scores before treatment（P<0.05）;p65 expression was negatively correlated with efficacy subgroups,and positively correlated with pretreatment LDH levels,Ann-Arbor subgroup,ECOG subgroup,extra-nodal invasion,IPI scores,and huge mass（P<0.05）．IPI and p65 score were independent prognostic risk factors for overall survival（OS） in DLBCL patients（P<0.05）．The mean value of OS was the lowest in patients in the YAP-/p65⁺ group in the co-expression stratification．Conclusions Low expression of YAP or high expression of p65 suggests larger tumor load and poorer outcome and prognosis in patients for DLBCL．

Key words: DLBCL, Hippo pathway, YAP, NF-κB, p65

何人可, 林子怡, 张闻开, 陈远林, 张东辉, 邓晓芳. YAP、p65与弥漫大B细胞淋巴瘤临床特征的相关性及临床意义[J]. 广州医药, 2024, 55(12): 1389-1396.

HE Renke, LIN Ziyi, ZHANG Wenkai, CHEN Yuanlin, ZHANG Donghui, DENG Xiaofang. Correlation and clinical significance of YAP and p65 with clinical features of diffuse large B-cell lymphoma[J]. Guangzhou Medical Journal, 2024, 55(12): 1389-1396.

参考文献

[1] SEHN L H,SALLES G.Diffuse large B-cell lymphoma[J].N Engl J Med,384(9):842-858.
[2] THANDRA K C,BARSOUK A,SAGINALA K,et al.Epidemiology of non-hodgkin's lymphoma[J].Med Sci,2021,9(1):5.
[3] CRUMP M,NEELAPU S S,FAROOQ U,et al.Outcomes in refractory diffuse large B-cell lymphoma:Results from the international SCHOLAR-1 study[J].2018,131(5):587-588.
[4] MORIN R D,ASSOULINE S,ALCAIDE M,et al.Genetic landscapes of relapsed and refractory diffuse large B-Cell Lymphomas[J].Clin Cancer Res,2016,22(9):2290-2300.
[5] KULKARNI A,CHANG M T,VISSERS J H A,et al.The hippo pathway as a driver of select human cancers[J].Trends Cancer,2020,6(9):781-796.
[6] HU X,ZHANG Y,YU H,et al.The role of YAP1 in survival prediction,immune modulation,and drug response:A pan-cancer perspective[J].Front Immunol,2022(13):1012173.
[7] MORIYAMA K,HORI T.BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells[J].Int J Hematol,2019,110(5):591-598.
[8] KYRIAZOGLOU A,NTANASIS-STATHOPOULOS I,TERPOS E,et al.Emerging insights into the role of the hippo pathway in multiple myeloma and associated bone disease[J].Clin Lymphoma Myeloma Leuk,2020,20(2):57-62.
[9] TANIGUCHI K,KARIN M.NF-κB,inflammation,immunity and cancer:Coming of age[J].Nat Rev Immunol,2018,18(5):309-324.
[10] ZHANG T,MA C,ZHANG Z,et al.NF-κB signaling in inflammation and cancer[J].MedComm,2021,2(4):618-653.
[11] CHEN R,ZHOU D,WANG L,et al.MYD88L265P and CD79B double mutations type(MCD type)of diffuse large B-cell lymphoma:mechanism,clinical characteristics,and targeted therapy[J].Ther Adv Hematol,2022(13):20406207211072839.
[12] GAO Y,YANG Y,YUAN F,et al.TNFα-YAP/p65-HK2 axis mediates breast cancer cell migration[J].Oncogenesis,2017,6(9):e383.
[13] CHANG T Y,WU C T,SHEU M L,et al.CARMA3 promotes colorectal cancer cell motility and cancer stemness via yap-mediated NF-κB activation[J].Cancers,2021,13(23):5946.
[14] ZHAO T,WANG Z,FANG J,et al.HTLV-1 activates YAP via NF-κB/p65 to promote oncogenesis[J].Proc Natl Acad Sci U S A,2022,119(9):e2115316119.
[15] BOUVIER C,MACAGNO N,NGUYEN Q,et al.Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma[J].Oncotarget,2016,7(40):64702-64710.
[16] KIM M K,JANG J W,BAE S C.DNA binding partners of YAP/TAZ[J].BMB Rep,2018,51(3):126-133.
[17] OKAZAKI T,KAGEJI T,KUWAYAMA K,et al.Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma[J].Cancer Lett,2012,323(2):199-207.
[18] KESHET R,ADLER J,RICARDO LAX I,et al.c-Abl antagonizes the YAP oncogenic function[J].Cell Death Differ,2015,22(6):935-945.
[19] DAVIES A,CUMMIN T E,BARRANS S,et al.Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma(REMoDL-B):An open-label,randomised,phase 3 trial[J].Lancet Oncol,2019,20(5):649-662.
[20] VITOLO U,WITZIG T E,GASCOYNE R D,et al.ROBUST:First report of phase III randomized study of lenalidomide/R-CHOP(R2-CHOP)vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma[J].Hematol Oncol,2019,37(S2):36-37.
[21] WANG J,ZHOU M,ZHANG Q G,et al.Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients[J].Oncotarget,2017,8(6):9708-9716.
[22] CALSES P C,CRAWFORD J J,LILL J R,et al.Hippo pathway in cancer:Aberrant regulation and therapeutic opportunities[J].Trends Cancer,2019,5(5):297-307.

YAP、p65与弥漫大B细胞淋巴瘤临床特征的相关性及临床意义

Correlation and clinical significance of YAP and p65 with clinical features of diffuse large B-cell lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价